Since the discovery of liposomes, these vesicular carriers have attracted the researchers from all the vistas of the
biomedical domain to explore and harness the potential benefits. Many novel drug delivery-based products have been
approved by the United States Food and Drug Administration (US-FDA) and other federal agencies of the globe, out of
which the major share is of the liposomes and related carriers. Taking cognizance of it, the US-FDA has recently come up
with ‘Guidance for Industry on Liposome Drug Products’. In cancer management, chemotherapy is the most frequently
employed approach which is still not devoid of untoward challenges and side effects. In chemotherapy, the taxanes, esp.
Docetaxel shares a huge percentage in the prescription pattern. Also, the first marketed liposomal product was encasing one
drug of this category. Henceforth, the present review will highlight the advances in the delivery of taxanes, in particular
docetaxel, with an emphasis on the need, success and pharmacoeconomic aspects of such vesicular-carrier mediated
docetaxel delivery.